-
Signature
-
/s/ Janet Dillione
-
Issuer symbol
-
CRMD
-
Transactions as of
-
09 Dec 2025
-
Net transactions value
-
-$142,100
-
Form type
-
4
-
Filing time
-
11 Dec 2025, 08:38:24 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Dillione Janet |
Director |
C/O CORMEDIX INC.,, 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS |
/s/ Janet Dillione |
11 Dec 2025 |
0001489798 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CRMD |
Common Stock |
Options Exercise |
$181,450 |
+19,000 |
+39% |
$9.55 |
67,473 |
09 Dec 2025 |
Direct |
|
| transaction |
CRMD |
Common Stock |
Options Exercise |
$84,450 |
+15,000 |
+22% |
$5.63 |
82,473 |
09 Dec 2025 |
Direct |
|
| transaction |
CRMD |
Common Stock |
Sale |
$408,000 |
-34,000 |
-41% |
$12.00 |
48,473 |
09 Dec 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CRMD |
Stock Option (Right to Buy Common Stock) |
Options Exercise |
$0 |
-19,000 |
-100% |
$0.000000 |
0 |
09 Dec 2025 |
Common Stock |
19,000 |
$9.55 |
Direct |
F2 |
| transaction |
CRMD |
Stock Option (Right to Buy Common Stock) |
Options Exercise |
$0 |
-15,000 |
-100% |
$0.000000 |
0 |
09 Dec 2025 |
Common Stock |
15,000 |
$5.63 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: